- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Actavis (NYSE: ACT) hit a new 52-week high Wednesday as it is currently trading at $91.52, above its previous 52-week high of $91.47 with 733,444 shares traded as of 1:07 p.m. ET. Average volume has been 1.3 million shares over the past 30 days. Actavis has a market cap of $11.3 billion and is part of the health care sector and drugs industry. Shares are up 4.8% year to date as of the close of trading on Tuesday. Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has a P/E ratio of 116.3, above the S&P 500 P/E ratio of 17.7.